PF-562271 HCl: Precision Tools for FAK/Pyk2 Inhibitor Workflows in Cancer Research

Principle Overview: Targeting FAK/Pyk2 Signaling in Cancer

PF-562271 HCl is a potent, reversible, ATP-competitive inhibitor designed to selectively target focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), two non-receptor tyrosine kinases that orchestrate key cellular processes including adhesion, migration, proliferation, and survival (product_spec). With an IC50 of 1.5 nM for FAK and 14 nM for Pyk2, PF-562271 HCl demonstrates over 100-fold selectivity against most kinases, positioning it as a gold-standard tool in dissecting focal adhesion kinase signaling pathways, particularly within cancer research contexts where tumor growth inhibition and microenvironment modulation are critical (advanced_science).

Step-by-Step Experimental Workflow for PF-562271 HCl

To maximize PF-562271 HCl's potential, a robust experimental design is essential. Below is a recommended workflow for cell-based and in vivo oncology assays, leveraging the compound's solubility, potency, and selectivity.

1. Compound Preparation: Dissolve PF-562271 HCl in DMSO at a concentration of ≥26.35 mg/mL with gentle warming. Avoid water or ethanol as solvents due to poor solubility (product_spec).
2. Cell-Based Assays: Pre-treat cultured cancer cell lines (e.g., NSCLC, melanoma, or gastric carcinoma models) with serial dilutions (0.5–5 μM) to determine dose-dependent FAK phosphorylation inhibition. Incubate for 2–24 hours depending on readout (source: benchmark_guide).
3. Western Blot/Immunofluorescence: Quantify FAK and Pyk2 phosphorylation status post-treatment using phospho-specific antibodies. Normalize results to total protein to assess efficacy (source: protocol_guide).
4. In Vivo Xenograft Models: Administer PF-562271 HCl via oral gavage or intraperitoneal injection at 10–50 mg/kg/day. Monitor tumor growth, metastasis, and FAK phosphorylation in tumor tissues (source: advanced_science).
5. Combination Therapy: Integrate PF-562271 HCl treatment with radiotherapy or immune checkpoint blockers (e.g., anti-PD-1 or anti-TIGIT) to probe synergistic antitumor effects and immune memory, as supported by emerging preclinical evidence (reference_study).

Protocol Parameters

• assay | 1.5 nM IC50 (FAK), 14 nM IC50 (Pyk2) | kinase selectivity profiling | Defines optimal inhibitor concentrations for target engagement | product_spec
• cell-based assay | 0.5–5 μM PF-562271 HCl | adherent cancer cell lines | Recommended for dose-response and signaling studies | workflow_recommendation
• in vivo administration | 10–50 mg/kg/day | mouse xenograft models | Achieves dose-dependent tumor growth inhibition and FAK phosphorylation suppression | advanced_science
• compound solubilization | ≥26.35 mg/mL in DMSO, gentle warming | all applications | Ensures maximal solubility and reproducibility | product_spec
• storage | -20°C (desiccated) | compound stock | Preserves inhibitor stability for long-term use | product_spec

Key Innovation from the Reference Study

The pivotal study by Wang et al. (2025) (Cancer Letters) illuminates how radiotherapy, when combined with dual immune checkpoint blockade (anti-PD-1 and anti-TIGIT), drives robust abscopal effects and durable immune memory via CD8+ T cells. This triple approach amplifies tumor regression, enhances systemic antitumor immunity, and fosters central memory T cells, underpinning long-term recurrence prevention. For PF-562271 HCl users, this insight suggests integrating FAK/Pyk2 inhibition into multi-modal regimens to modulate the tumor microenvironment, enhance CD8+ T cell infiltration, and potentially overcome resistance to immunotherapy. Practically, co-administering PF-562271 HCl with radiotherapy and immune modulators in preclinical models offers a high-fidelity platform to dissect tumor-immune crosstalk and evaluate combination efficacy in translational oncology workflows.

Advanced Applications & Comparative Advantages

The unique selectivity profile of PF-562271 HCl empowers researchers to interrogate FAK/Pyk2-driven pathways with minimal off-target effects (product_spec). In comparative studies, this compound exhibits >100-fold selectivity over other kinases—except for certain CDKs (benchmark_guide). This makes it ideal for:

• Tumor Growth Inhibition: Dose-dependent suppression of tumor proliferation and metastasis in xenograft and transgenic mouse models (source: advanced_science).
• FAK Phosphorylation Inhibition: EC50 of 93 ng/mL for suppressing FAK phosphorylation, enabling precise modulation of cell adhesion and migration (source: product_spec).
• Tumor Microenvironment Modulation: FAK/Pyk2 inhibition disrupts stromal and immune cell interactions, sensitizing tumors to immunotherapy and radiotherapy, as highlighted in the reference study (reference_study).

For a comprehensive overview of strategic deployment and mechanistic insights, see the in-depth article "Redefining Cancer Research: Harnessing PF-562271 HCl", which extends the translational relevance of FAK/Pyk2 inhibition by integrating ERK-mediated tumor cell death and resistance mechanisms. Meanwhile, the workflow-focused guide "PF-562271 HCl (SKU A8345): Precision FAK/Pyk2 Inhibition" complements this narrative by addressing assay reproducibility and practical troubleshooting in real-world cancer biology labs.

Troubleshooting & Optimization Tips

• Solubility Issues: To prevent precipitation, dissolve PF-562271 HCl in DMSO at concentrations up to ≥26.35 mg/mL with gentle warming. Avoid aqueous buffers or ethanol (product_spec).
• Batch Variability: Use fresh aliquots and minimize freeze-thaw cycles. Store desiccated at -20°C for maximum stability (product_spec).
• Off-Target Effects: While highly selective, PF-562271 HCl may inhibit certain CDKs at high concentrations; titrate doses and include kinase activity controls to validate specificity (benchmark_guide).
• Assay Sensitivity: Normalize phospho-FAK/Pyk2 readouts to total protein levels and replicate experiments across independent batches to ensure reproducibility (protocol_guide).
• Combination Studies: When combining with radiotherapy or immune modulators, stagger administration to allow for adequate pharmacodynamic assessment, and monitor for synergistic toxicity (workflow_recommendation).

For further troubleshooting guidance and troubleshooting in advanced cancer assays, refer to the scenario-driven workflows in PF-562271 HCl (SKU A8345): Precision FAK/Pyk2 Inhibition, which complements this article’s focus on assay reliability.

Why Choose PF-562271 HCl from APExBIO?

APExBIO is a trusted global supplier of high-quality research biochemicals, and PF-562271 HCl (SKU: A8345) is batch-validated for reproducibility, selectivity, and purity. Researchers benefit from detailed technical support, transparent documentation, and access to validated workflows to accelerate discovery in cancer biology and drug development.

Future Outlook: Translational Impact and Evolving Workflows

The evolving paradigm in oncology underscores the importance of precision-targeted inhibitors like PF-562271 HCl in combination regimens. The reference study's demonstration of enhanced abscopal effects and immune memory via radiotherapy and dual checkpoint blockade (reference_study) paves the way for integrated experimental designs that interrogate not just tumor cell-intrinsic mechanisms, but also the immune contexture driving relapse and resistance. Looking forward, PF-562271 HCl will remain central to workflows exploring tumor-immune crosstalk, biomarker-driven stratification, and the rational design of next-generation anti-cancer therapies—cementing its role as a cornerstone in translational oncology research.